To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
MorphoSys Strengthens Patent Position on its Core Technologies in Japan
Read time: Less than a minute
MorphoSys AG has announced that the Japanese Patent Office has granted a new patent covering its CysDisplay® technology. CysDisplay® is a proprietary screening technology, which is an important component of MorphoSys's proprietary HuCAL platform.
The new patent (JP 4312403) entitled "Novel Methods for Displaying (Poly) Peptides/Proteins on Bacteriophage Particles" describes a selection technology based on phage display for selecting high affinity antibodies.
The claims are not limited to the use of a HuCAL library with this selection technology. Additional applications, including continuation applications, are currently pending in different countries.
"This new patent expands the protection of our proprietary core technology HuCAL in Asia. Over the last few years we have built a strong intellectual property portfolio around our proprietary technology HuCAL, which lies at the heart of our successful partnership-based business model. We expect to continue to strengthen still further our IP position in this important market for antibody-based products and services," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.
MorphoSys's HuCAL libraries are collections of diverse, fully human synthetic antibodies, whose modular CDR designs facilitate systematic engineering of antibody properties. The company's most advanced marketed version, HuCAL PLATINUM, provides access to fully human antibodies as research tools, diagnostics and therapeutics.
The new patent (JP 4312403) entitled "Novel Methods for Displaying (Poly) Peptides/Proteins on Bacteriophage Particles" describes a selection technology based on phage display for selecting high affinity antibodies.
The claims are not limited to the use of a HuCAL library with this selection technology. Additional applications, including continuation applications, are currently pending in different countries.
"This new patent expands the protection of our proprietary core technology HuCAL in Asia. Over the last few years we have built a strong intellectual property portfolio around our proprietary technology HuCAL, which lies at the heart of our successful partnership-based business model. We expect to continue to strengthen still further our IP position in this important market for antibody-based products and services," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.
MorphoSys's HuCAL libraries are collections of diverse, fully human synthetic antibodies, whose modular CDR designs facilitate systematic engineering of antibody properties. The company's most advanced marketed version, HuCAL PLATINUM, provides access to fully human antibodies as research tools, diagnostics and therapeutics.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
